DSpace university logo mark
Advanced Search
Japanese | English 

NAOSITE : Nagasaki University's Academic Output SITE > University Hospital > Articles in academic journal >

Efficacy of ME1036 against meticillin-resistant Staphylococcus aureus and vancomycin-insensitive S. aureus in a model of haematogenous pulmonary infection.


File Description SizeFormat
IJAA32_401.pdf425.57 kBAdobe PDFView/Open

Title: Efficacy of ME1036 against meticillin-resistant Staphylococcus aureus and vancomycin-insensitive S. aureus in a model of haematogenous pulmonary infection.
Authors: Yanagihara, Katsunori / Ohnishi, Yuriko / Morinaga, Yoshitomo / Nakamura, Shigeki / Kurihara, Shintaro / Seki, Masafumi / Izumikawa, Koichi / Kakeya, Hiroshi / Yamamoto, Yoshihiro / Yamada, Yasuaki / Kohno, Shigeru / Kamihira, Shimeru
Issue Date: Nov-2008
Publisher: Elsevier B.V.
Citation: International journal of antimicrobial agents, 32(5), pp.401-404; 2008
Abstract: ME1036, a novel parenteral carbapenem, was developed for the treatment of meticillin-resistant Staphylococcus aureus (MRSA) and vancomycin-intermediate S. aureus (VISA). A model of haematogenous pulmonary infection was induced in mice by tail vein injection of MRSA strain NUMR101 or VISA Mu50 enmeshed in agar beads. After 24h of infection, mice were treated twice daily for 7 days with 200mg/kg/day vancomycin (VCM) or ME1036. Mice infected with VISA were also pre-treated with cyclophosphamide to induce an immunocompromised state. The number of viable bacteria in the lungs was counted 12h after the final drug treatment. VCM decreased the number of viable MRSA in the lungs in comparison with the control, although the difference was not significant (mean+/-standard error of the mean log(10) colony-forming units (CFU)/lung=6.876+/-0.54 vs. 8.25+/-0.41, respectively). In contrast, treatment with ME1036 resulted in a significant decrease in the number of viable MRSA (log(10)CFU/lung=2.69+/-0.44 (n=6); P<0.0001) compared with both the VCM-treated and control mice. In the VISA-infected mice, ME1036 significantly reduced the number of viable bacteria compared with VCM and control (log(10)CFU/lung=3.65+/-0.68 for ME1036 vs. 5.71+/-0.75 for VCM (P<0.05) and 7.07+/-0.45 for control (P<0.001)). ME1036 produced >3 log(10) reduction versus control against both MRSA strains (>5 log for the VCM-susceptible strain and 3.4 log for the VISA), whereas VCM produced <1.3 log for both strains.
Keywords: ME1036 / MRSA / Pulmonary infection / Staphylococcus aureus / Vancomycin-intermediate
URI: http://hdl.handle.net/10069/23056
ISSN: 09248579
DOI: 10.1016/j.ijantimicag.2008.04.030
PubMed ID: 18715761
Rights: Copyright © 2008 Elsevier B.V. and the International Society of Chemotherapy All rights reserved.
Type: Journal Article
Text Version: author
Appears in Collections:Articles in academic journal

Citable URI : http://hdl.handle.net/10069/23056

All items in NAOSITE are protected by copyright, with all rights reserved.

 

Valid XHTML 1.0! Copyright © 2006-2015 Nagasaki University Library - Feedback Powerd by DSpace